1. The Nurse View

3. Ovarian Cancer in the United States

4. FDA-Approved Drugs for Ovarian Cancer

5. Case Study Deborah

6. Genetic Testing in Ovarian Cancer

7. Case Study Deborah (cont)

8. Primary Systemic Therapy Options Stage IV Ovarian Cancer

9. Case Study Deborah (cont)

10. Treatment by Platinum Status at Recurrence

11. Case Study Deborah (cont)

12. PARP Inhibitors for Ovarian Cancer Overview

13. Maintenance Therapy Recommendations NCCN Guidelines

14. Initiating PARP Inhibitor Therapy Patient Education for Oral Medications

15. PARP Inhibitors Safety

16. Case Study Deborah (cont)

17. Managing GI Toxicity From PARP Inhibitors

18. Managing Anemia From PARP Inhibitors

19. Case Study Jane

20. Considerations for Elderly Patients

21. Case Study Jane (cont)

22. Signs and Symptoms of Thrombocytopenia

23. Managing Thrombocytopenia From Niraparib

24. Niraparib Dose Adjustments

25. Laboratory Abnormalities Associated With PARP Inhibitors

26. Key Takeaways

27. Resources for Patients and Oncology Nurses

28. Additional Online Resources

29. Abbreviations

30. Abbreviations (cont)